Dizal Reveals Promising Hematology Pipeline Developments at ASH 2025 Dizal Pharmaceuticals showcased new advancements in its hematology pipeline, presenting promising data on golidocitinib and birelentinib during ASH 2025.

Dizal Reveals Promising Hematology Pipeline Developments at ASH 2025 #China #Shanghai #Dizal #Golidocitinib #SSE688192

Dizal Unveils Groundbreaking Lung Cancer Treatments at 2025 WCLC Conference At the 2025 World Conference on Lung Cancer, Dizal presented innovations in treating non-small cell lung cancer, showcasing promising results with ZEGFROVY and golidocitinib.

Dizal Unveils Groundbreaking Lung Cancer Treatments at 2025 WCLC Conference #China #Shanghai #Dizal #Golidocitinib #ZEGFROVY

Dizal Unveils Groundbreaking Hematologic Cancer Therapies at EHA and ICML 2025 Dizal Pharmaceutical showcases two innovative treatments, golidocitinib and DZD8586, presenting their promising results in hematologic malignancies at major international conferences.

Dizal Unveils Groundbreaking Hematologic Cancer Therapies at EHA and ICML 2025 #None #DZD8586 #Dizal #Golidocitinib

Dizal Unveils Promising Clinical Results for Lymphoma Treatments at Upcoming Global Conferences Dizal will showcase recent clinical data on golidocitinib and DZD8586, targeting lymphoma treatments, at major international hematology conferences.

Dizal Unveils Promising Clinical Results for Lymphoma Treatments at Upcoming Global Conferences #China #Shanghai #DZD8586 #Dizal #Golidocitinib

Dizal's Golidocitinib Emerging as a Strong Contender for NSCLC Treatment Resistant to Immunotherapies Dizal's golidocitinib, a JAK1 inhibitor, shows promise in treating NSCLC patients resistant to anti-PD-1 therapies. Results expected at ELCC 2025.

Dizal's Golidocitinib Emerging as a Strong Contender for NSCLC Treatment Resistant to Immunotherapies #China #Shanghai #NSCLC #Dizal #Golidocitinib